S-Adenosylmethionine (Ademetionine) in Psychiatric Disorders: Historical Perspective and Current Status

CNS Drugs

Volumn 6, Issue 6, 1996, Pages 416-425

  Spillmann, Maya ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; S ADENOSYLMETHIONINE;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; DEMENTIA; DEPRESSION; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; MANIA; MENTAL DISEASE; MOOD; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0030444194     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199606060-00002     Document Type: Review

References (85)

1. Friedel HA, Goa KL, Benfield P. S-Adenosyl-L-methionine: a review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989; 38 (3): 389-416
2. Baldessarini RJ. Neuropharmacology of S-adenosyl-L-methionine. Am J Med 1987; 83 Suppl. 5A: 95-103
3. Baldessarini RJ, Kopin IJ. S-Adenosylmethionine in brain and other tissues. J Neurochem 1966; 13: 769-77
4. Baldessarini RJ. Biological transmethylation involving S-adenosylmethionine: development of assay methods and implications for neuropsychiatry. Int Rev Neurobiol 1975; 18: 41-67
5. Stryer L. Biochemistry. New York: Freeman, W H and Company, 1995
6. Cantoni GL. S-adenosylmethionine; a new intermediate formed enzymatically from L-methionine and adenosine triphosphate. J Bio Chem 1953; 204: 403-16
7. Chawla RK, Bonkovsky HL, Galambos JT. Biochemistry and pharmacology of S-adenosyl-L-methionine and rationale for its use in liver disease. Drugs 1990; 40 Suppl. 3: 98-110
8. Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994; 48 (2): 137-52
9. Cimino M, Vantini G, Algeri S, et al. Age related modification of dopaminergic and β-adrenergic receptor system: restoration to normal activity by modifying membrane fluidity with SAMe. Life Sci 1984; 34: 2029-39
10. Otero-Losada ME, Rubio MC. Acute changes in 5-HT metabolism after S-adenosylmethionine administration. Gen Pharmacol 1989; 20: 403-6
11. Otero-Losada ME, Rubio MC. Acute effects of S-adenosylmethionine on catecholaminergic central function. Eur J Pharmacol 1990; 163: 353-6
12. Curcio M, Catto E, Stramentinoli G, et al. Effect of S-adenosyl-L-methionine on serotonin metabolism in rat brain. Prog Neuropsychopharmacol 1978; 2: 65-71
13. McKeever MP, Weir DG, Molloy AM, et al. Betaine-homocysteine methyltransferase: organ distribution in man, pig and rat and subcellular distribution in the rat. Clin Sci 1991; 81 (4): 551-6
14. Reynolds EH, Stramentinoli G. Folic acid, S-adenosylmethionine and affective disorders. Psychol Med 1983; 13 (4): 705-10
15. Shorvon SD, Carney MWP, Chanarin I, et al. The neuropsychiatry of megaloblastic anaemia. BMJ 1980; 281: 1036-8
16. Bottiglieri T, Hyland K. S-adenosylmethionine levels in psychiatrie and neurological disorders: a review. Acta Neurol Scand 1994; Suppl. 154: 19-26
17. Bottiglieri T, Laundy M, Martin R, et al. S-adenosylmethionine influences monoamine metabolism [letter]. Lancet 1984; II: 224
18. Bottiglieri T, Chary TK, Laundy M, et al. Transmethylation in depression. Ala J Med Sci 1988; 25 (3): 296-301
19. Jacobsen S, Danneskiold-Samsøe B, Bach Andersen R. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol 1991; 20: 294-302
20. Maes M, Meltzer HY. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology, the fourth generation of progress. 4th ed. New York: Raven Press Ltd, 1995: 933-44
21. Schatzberg AF, Schildkraut JJ. Recent studies on norepinephrine in mood disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology, the fourth generation of progress. 4th ed. New York: Raven Press Ltd, 1995: 911-20
22. Willner P. Dopaminergic mechanism in depression and mania. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology, the fourth generation of progress. 4th ed. New York: Raven Press Ltd, 1995: 921-32
23. Baldessarini R, Stramentinoli G, Lipinski JF. Methylation in schizophrenia: an old hypothesis revisited. In: Zappia V, editor. Biochemical and pharmacological roles of adenosylmethionine and the central nervous system. Oxford: Pergamon Press, 1979: 127-40
24. Baldessarini RJ, Stramentinoli G, Lipinski JF. Methylation hypothesis. Arch Gen Psychiatry 1979; 36: 303-7
25. Stramentinoli G, Baldessarini RJ. Lack of enhancement of dimethyltryptamine formation in rat brain and rabbit lung in rim by methionine or S-adenosylmethionine. J Neurochem 1978; 31: 1015-20
26. Bottiglieri T, Godfrey P, Flynn T, et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990; 53: 1096-8
27. Castagna A, Le Grazie C, Accordini P, et al. Cerebrospinal fluid S-adenosylmethionine (SAMe) and glutathionine concentrations in HIV infection: effect of treatment with parenteral SAMe. Neurology 1995; 45: 1678-83
28. Lever EG, Elwes RDC, Williams A, et al. Subacute combined degeneration of the cord due to folate deficiency: response to methyl folate treatment. J Neurol Neurosurg Psychiatry 1986 Oct; 49: 1203-7
29. Keating JN, Trimble KC, Mulcahy F, et al. Evidence of brain methyltransferase inhibition and early involvement in HIV-positive patients. Lancet 1991; 337: 935-9
30. Bottiglieri T, Reynolds EH, Toone BK, et al. CSF S-adenosylmethionine in neuropsychiatrie disorders [letter]. Lancet 1991; 338: 121
31. Stramentinoli G. Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamics. Am J Med 1987; 83 (5A): 35-42
32. Carney MWP, Chary TKN, Bottiglieri T, et al. Switch mechanism in affective illness and oral S-adenosylmethionine (SAM). Br J Psychiatry 1987; 150: 724-5
33. Bell KM, Potkin SG, Carreon D, et al. S-adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurol Scand 1994; Suppl. 154: 15-8
34. Matthysse S, Baldessarini RJ. S-adenosylmethionine and catechol-O-methyl-transferase in schizophrenia. Am J Psychiatry 1972; 128: 1310-2
35. Tolbert LC. MAT kinetics in affective disorders and schizophrenia: an account. Ala J Med Sci 1988; 25 (3): 291-5
36. Carney MWP. Neuropharmacology of S-adenosyl methionine. Clin Neuropharmacol 1986; 9 (3): 235-43
37. Coppen A, Abou-Saleh M. Plasma folate and affective morbidity during long-term lithium therapy. Br J Psychiatry 1982; 141: 87-9
38. Levitt AJ, Joffe RT. Folate, B12, and life course of depressive illness. Biol Psychiatry 1989; 25: 867-72
39. Ordonez LA, Wurtman RJ. Folic acid deficiency and methyl group metabolism in rat brain: effects of L-dopa. Arch Biochem Biophys 1974; 160 (2): 372-6
40. Osmond H, Smythies J. Schizophrenia: a new approach. J Ment Sci 1952; 98: 309-15
41. Smythies JR. Recent advances in the biochemistry of psychosis. Lancet 1960; Jun 11: 1287-9
42. Smythies JR. Recent advances in the biochemistry of schizophrenia. Guy's Gazette 1966; May 14: 242-7
43. Smythies JR. The transmethylation hypothesis and one-carbon cycle hypothesis of schizophrenia. Psychol Mod 1983; 13: 711-4
44. Cohen SM, Nichols A, Wyatt R, et al. The administration of methionine to chronic schizophrenic patients: a review of ten studies. Biol Psychiatry 1974; 8: 209-25
45. Andreoli VM, Maffei F, Tonon GC. SAMe blood levels in schizophrenia and depression. In: Andreoli VM, Agnoli A, Fazio C, editors. Transmethylations and the central nervous system. New York: Springer Verlag, 1978: 147-50
46. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 2nd ed. Washington, DC: American Psychiatric Association, 1968
47. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
48. Fazio C, Andreoli V, Agnoli A, et al. Therapeutic effects and mechanism of S-adenosylmethionine (SAMe) in depressive disorders [in Italian]. Minerva Med 1971; 64 (29): 1515-29
49. Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand 1994; Suppl. 154: 7-14
50. Salvadorini F, Galeone F, Saba P, et al. Evaluation of S-adenosylmethionine (SAMe) effectiveness on depression. Curr Ther Res 1980; 27: 908-18
51. Lipinski JF, Cohen UM, Frankenburg F, et al. Open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry 1984; 141 (3): 448-50
52. Agnoli A, Fazio C, Andreoli V, et al. Neuropsychiatric disorders and transmethylation: therapeutic effects of S-adenosyl-L-methionine [in Italian]. Clin Ter 1975; 75 (6): 567-79
53. Fava M, Giannelli A, Rapisarda V, et al. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. Psychiatry Res 1995; 56: 295-7
54. Barberi A, Pusateri C. Clinical effects of S-adenosyl-L-methionine (SAMe) in depressive disorders [in Italian]. Minerva Psichiatr 1978; 19: 235-43
55. Salmaggi P, Bressa GM, Nicchia G, et al. Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. Psychother Psychosom 1993; 59: 34-40
56. Fava M, Rosenbaum JF, Birnbaum R, et al. The thyrotropin response to thyrotropin-releasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatr Scand 1992; 86: 42-5
57. Janicak PG, Lipinski J, Davis JM, et al. S-adenosylmethionine in depression. A literature review and preliminary report. Ala J Med Sci 1988; 25 (3): 306-12
58. Agnoli A, Andreoli V, Casacchia M, et al. Effect of S-adenosyl-L-methionine (SAMe) upon depressive symptoms. J Psychiatr Res 1976; 13: 43-54
59. Caruso I, Fumagalli M, Boccassini L, et al. Antidepressant activity of S-Adenosyl methionine [letter]. Lancet 1984; 1: 904
60. Carney MWP, Edeh J, Bottiglieri T, et al. Affective illness and S-adenosylmethionine: a preliminary report. Clin Neuropharmacol 1986; 9 (4): 379-85
61. Kagan BL, Sultzer DL, Rosenlicht N, et al. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatr 1990; 147: 591-5
62. Bell MB, Carreon D, Plon L, et al. Oral s-adenosylmethionine in the treatment of depression: a double-blind comparison with desipramine. Study report. BioResearch File. 3rd ed. 1990: 53-4
63. De Vanna M, Rigamonti R. Oral S-adenosyl-L-methionine in depression. Curr Ther Res 1992; 52 (3): 478-85
64. Bell KM, Plon L, Bunney WEJ, et al. S-adenosylmethionine treatment of depression: a controlled clinical trial. Am J Psychiatry 1988; 145 (9): 1110-4
65. Mantero M, Pastorino P, Carolei A, et al. Controlled double-blind study (SAMe-imipramine) in depression syndromes [in Italian]. Minerva Med 1975; 66: 4098-101
66. Monaco P, Quattrocchi F. Study of the antidepressive effects of a biological transmethylating agent (S-adenosyl-methionine or SAM) [in Italian]. Riv Neurol 1979; 49: 417-39
67. Miccoli L, Porro V, Bertolino A. Comparison between the antidepressant activity of S-adenosylmethionine (SAMe) and that of some tricyclic drugs. Acta Neurol Napoli 1978; 33: 243-55
68. Scarzella R, Appiotti A. A double-blind clinical comparison of SAMe vs. clomipramine in depressive disorders [in Italian]. Riv Sper Freniatr 1978; 102: 359-65
69. Calandra C, Roxas M, Rapisarda V. Antidepressant action of SAM in comparison to chlorimipramine. Hypotheses to interpret the mechanism of action [in Italian]. Minerva Psichiatr 1979; 20 (2): 147-52
70. Scaggion G, Baldan L, Domanin S. Antidepressive action of S-adenosylmethionine compared to nomifensine maleate [in Italian]. Minerva Psichiatr 1982; 23 (2): 93-7
71. De Leo D. S-adenosylmethionine as an antidepressant - a double blind trial versus placebo. Curr Ther Res 1987; 41: 865-70
72. Rosenbaum J, Fava M, Falk WE, et al. The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand 1990; 81: 432-6
73. Rocco PL. Major depression complicating medical illness: utility of S-adenosyl-L-methionine. Neuropsychopharmacology 1994; 10 Suppl Pt 2: 99
74. Torta R, Zanalda E, Rocca P, et al. Inhibitory activity of S-adenosyl-L-methionine on serum gamma-glutamyl-trans-peptidase increase induced by psychodrugs and anticonvulsants. Curr Ther Res 1988; 44: 144-59
75. Alvarez E, Udina C, Guillamat R. Shortening of latency period in depressed patients treated with SAMe and other antidepressant drugs. Cell Bio Rev 1987; S1: 103-10
76. Berlanga C, Ortega-Soto HA, Ontiveros M, et al. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res 1992; 44 (3): 257-62
77. Cerutti R, Sichel MP, Perin M, et al. Psychological distress during puerperium: a novel therapeutic approach using S-adenosylmethionine. Curr Ther Res 1993; 53 (6): 707-16
78. Lo Russo A, Monaco M, Pani A, et al. Efficacy of S-adenosyl-L-methionine in relieving psychologic distress associated with detoxification on opiate abusers. Curr Ther Res 1994; 55 (8): 905-13
79. Agricola R, Dalla Verde G, Urani R, et al. S-adenosyl-L-methionine in the treatment of major depression complicating chronic alcoholism. Curr Ther Res 1994; 55 (1): 83-92
80. Crellin R, Bottiglieri T, Reynolds EH. Folates and psychiatric disorders. Drugs 1993; 45: 623-36
81. Cohen BM, Satlin A, Zubenko GS. S-adenosyl-L-methionine in the treatment of Alzheimer's disease. J Clin Psychopharmacol 1988; 8 (1): 43-7
82. Fontanari D, Di Palma C, Giorgetti G, et al. Effects of S-adenosyl-L-methioninc on cognitive and vigilance functions in elderly. Curr Ther Res 1994; 55 (6): 682-9
83. Reynolds EH, Carney MWP, Toone BK, et al. Transmethylation and neuropsychiatry. Cell Biol Rev 1987; 2: 93-102
84. Reynolds EH, Godfrey P, Bottiglieri T. S-adenosyl-methionine and Alzheimer's disease [abstract]. Neurology 1989; 39 Suppl. 1: 397
85. Carney MWP, Martin R, Bottiglieri T, et al. Switch mechanism in affective illness and S-adenosylmethionine. Lancet 1983; 1: 820-1